# Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

> **NCT00671112** · PHASE1 · TERMINATED · sponsor: **Brian Hill, MD, PhD** · enrollment: 30 (actual)

## Conditions studied

- 714leukemia
- Lymphoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00671112
- **Lead sponsor:** Brian Hill, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2015-10
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Treatment ineffective
- **Last updated:** 2015-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671112, "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00671112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*